

Lantheus Holdings, Inc. (LNTN)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001521036

Lantheus Holdings, Inc. LNTN; healthcare	
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 14.6; sampling error 2.5 points; lower is stronger
Rank	55 of 371
Profitability	C percentile 43.6
Solvency	B/C percentile 40.0
Growth and financing	A/B percentile 19.6
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$2.2B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$100.09 2026-10-08; market equity \$6.5B
Price used in grade	None



A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D from Mar 21, 2022, C/D from Feb 21, 2023, A/B from Mar 21, 2023, A from Apr 21, 2023

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals ("HCPs") Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 43.6						
Gross profitability		42.3%	32.2%	29.1	372	2025-12-31
Return on invested capital		22.7%	9.3%	12.3	74	2025-12-31
Accruals ratio		(7.4%)	(6.6%)	52.3	811	2025-12-31
Gross margin stability, five years		7.3 pts	2.8 pts	80.6	243	2025-12-31
Solvency, sleeve percentile 40.0						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		4.61	(0.31)	20.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.70x	2.96x	60.0	839	2025-12-31
Growth and financing, sleeve percentile 19.6						
Revenue growth, three-year compound		18.1%	10.0%	34.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Reinvestment rate		not computable	37.1%			latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31
Asset growth, three years		19.0%	2.1%	21.9	704	2025-12-31
Net share issuance, one year		(5.7%)	2.5%	2.8	634	2026-02-23

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
50	Insulet Corp. (PODD)	13.2	A	
51	Ardelyx, Inc. (ARDX)	13.5	A	
52	Resmed Inc. (RMD)	13.8	A	fortress balance sheet
53	Janux Therapeutics, Inc. (JANX)	14.1	A	
54	Treace Medical Concepts, Inc. (TMCI)	14.3	A	
55	Lantheus Holdings, Inc. (LNTH) <	14.6	A	
56	Harrow, Inc. (HROW)	14.9	A	late filer
57	Edwards Lifesciences Corp. (EW)	15.1	A	
58	Vertex Pharmaceuticals Inc. MA (VRTX)	15.4	A	
59	CareDx, Inc. (CDNA)	15.7	A	
60	Ensign Group, Inc. (ENSG)	15.9	A	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	96.8%	8.0%	86
Distance from 52-week high	(9.8%)	(31.4%)	84
EBIT to enterprise value	4.8%	(1.5%)	76
Free cash flow yield	4.0%	(1.0%)	74
Book value to price	0.20	0.28	40
Sales to price	0.24	0.31	43
Composite equity issuance, five years	(2.6%)	20.3%	24
Relative strength against the sector, log excess return	0.47	(0.14)	86

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$593.3M
Operating cash flow, four quarters	\$412.8M
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)

Median daily dollar volume, 63 sessions

\$105.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$942.0M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
2	assets	us-gaap:Assets	\$2.2B	2025-12-31	2026-02-26	10-K	0001193125-26-073498
3	operating income	us-gaap:OperatingIncomeLoss	\$310.8M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$310.8M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$80.2M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$568.7M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
7	book equity	us-gaap:StockholdersEquity	\$1.1B	2025-12-31	2026-02-26	10-K	0001193125-26-073498
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$359.1M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$565.3M	2024-12-31	2026-02-26	10-K	0001193125-26-073498
10	book equity	us-gaap:StockholdersEquity	\$1.1B	2024-12-31	2026-02-26	10-K	0001193125-26-073498
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$912.8M	2024-12-31	2026-02-26	10-K	0001193125-26-073498
12	net income	us-gaap:NetIncomeLoss	\$233.6M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$390.1M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
14	assets	us-gaap:Assets	\$2.0B	2024-12-31	2026-02-26	10-K	0001193125-26-073498
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5B	2025-12-31	2026-02-26	10-K	0001193125-26-073498
16	gross profit	us-gaap:GrossProfit	\$988.3M	2024-12-31	2026-02-26	10-K	0001193125-26-073498
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5B	2024-12-31	2026-02-26	10-K	0001193125-26-073498
18	gross profit	us-gaap:GrossProfit	\$709.5M	2023-12-31	2026-02-26	10-K	0001193125-26-073498
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.3B	2023-12-31	2026-02-26	10-K	0001193125-26-073498
20	gross profit	us-gaap:GrossProfit	\$581.7M	2022-12-31	2025-02-26	10-K	0001628280-25-007970
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$935.1M	2022-12-31	2025-02-26	10-K	0001628280-25-007970
22	gross profit	us-gaap:GrossProfit	\$187.7M	2021-12-31	2024-02-22	10-K	0001628280-24-006158
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$425.2M	2021-12-31	2024-02-22	10-K	0001628280-24-006158
24	current assets	us-gaap:AssetsCurrent	\$900.0M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
25	current liabilities	us-gaap:LiabilitiesCurrent	\$333.4M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$679.5M	2025-12-31	2026-02-26	10-K	0001193125-26-073498
27	liabilities	us-gaap:Liabilities	\$1.1B	2025-12-31	2026-02-26	10-K	0001193125-26-073498
28	operating income	us-gaap:OperatingIncomeLoss	\$364.6M	2023-12-31	2026-02-26	10-K	0001193125-26-073498
29	interest expense	us-gaap:InterestExpense	\$20.0M	2023-12-31	2024-02-22	10-K	0001628280-24-006158
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$305.3M	2023-12-31	2026-02-26	10-K	0001193125-26-073498
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$45.3M	2023-12-31	2024-02-22	10-K	0001628280-24-006158
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$281.8M	2022-12-31	2025-02-26	10-K	0001628280-25-007970
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$260.0M	2022-12-31	2024-02-22	10-K	0001628280-24-006158
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$53.9M	2021-12-31	2024-02-22	10-K	0001628280-24-006158
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$0	2021-12-31	2024-02-22	10-K	0001628280-24-006158
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$16.4M	2020-12-31	2023-02-23	10-K	0001628280-23-004698
37	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$0	2020-12-31	2023-02-23	10-K	0001628280-23-004698
38	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$7.4M	2016-12-31	2019-02-20	10-K	0001628280-19-001574
39	depreciation amortization	us-gaap:Depreciation	\$800,000	2016-12-31	2017-02-23	10-K	0001193125-17-053986
40	operating income	us-gaap:OperatingIncomeLoss	\$56.6M	2016-12-31	2019-02-20	10-K	0001628280-19-001574
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$26.3M	2016-12-31	2019-02-20	10-K	0001628280-19-001574
42	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.5M	2016-12-31	2019-02-20	10-K	0001628280-19-001574
43	current assets	us-gaap:AssetsCurrent	\$110.8M	2016-12-31	2018-02-26	10-K	0001628280-18-002261
44	current liabilities	us-gaap:LiabilitiesCurrent	\$43.8M	2016-12-31	2018-02-26	10-K	0001628280-18-002261
45	current assets	us-gaap:AssetsCurrent	\$90.0M	2015-12-31	2017-02-23	10-K	0001193125-17-053986
46	current liabilities	us-gaap:LiabilitiesCurrent	\$35.5M	2015-12-31	2017-02-23	10-K	0001193125-17-053986
47	assets	us-gaap:Assets	\$1.7B	2023-12-31	2025-02-26	10-K	0001628280-25-007970
48	assets	us-gaap:Assets	\$1.3B	2022-12-31	2024-02-22	10-K	0001628280-24-006158
49	shares outstanding	dei:EntityCommonStockSharesOutstanding	64,605,894	2026-02-23	2026-02-26	10-K	0001193125-26-073498
50	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,476,575	2025-02-20	2025-02-26	10-K	0001628280-25-007970